ArticleStem cell reports2025
GSK3α negatively regulates GSK3β by decreasing its protein levels and enzymatic activity in mouse embryonic stem cells.
Article in Stem cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Landscape of Glycogen Synthase Kinase-3β PET Tracers: Progress, Limitations, and Perspectives-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A critical role for STAT3 Thr714 phosphorylation in NPM-ALK-driven tumorigenesis.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Glycogen synthase kinase 3 (GSK3) is a crucial regulator of cellular processes, including stem cell maintenance and differentiation. Although the roles of the two GSK3 isozymes, GSK3α and GSK3β, are well documented, their specific interactions remain less understood. In this study, we explored the regulatory interplay between GSK3α and GSK3β in mouse embryonic stem cells (mESCs). Using genetic manipulation, small-molecule inhibitors, and biochemical analysis, we found that inhibition of GSK3α kinase activity increases GSK3β protein levels and activity, whereas overexpression of GSK3α reduces GSK3β protein levels and activity. Domain-swapping experiments between the two isozymes identified the glycine-rich region at the N terminus of GSK3α as the key sequence responsible for downregulating GSK3β protein levels. Our findings reveal a novel interaction between GSK3 isozymes, with GSK3α modulating GSK3β activity to maintain the balance between stem cell pluripotency and neural differentiation. This insight may open new pathways for understanding stem cell fate mechanisms and developing GSK3-targeted therapeutic strategies in regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.